📰 Column Group News
Page 7 - Column Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Column Group. Real-time updates on events, politics, business and more.
July 28, 2022
Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.
July 26, 2022
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
July 13, 2022
San Diego-based targeted protein degradation company Plexium said today that it has named a new member to its board of directors. The company said it appointed Brian Wong, the President and CEO of RAPT The
June 24, 2022
Rhode Island State Investment Commission, Providence, approved new alternative fund commitments totaling up to $46 million for the $10.3 billion Rhode Island Employees' Retirement System. The commission at its May 25 meeting approved commitments of up to $20 million to Crow Holdings Realty…
June 2, 2022
Surrozen (NASDAQ:SRZN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as […]
May 18, 2022
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
May 17, 2022
/PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the...
May 17, 2022
The funding will be used to advance the company's RNA processing drug discovery platform REMaster, along with its therapeutic pipeline.
March 2, 2022
/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical...
March 2, 2022
AGOURA HILLS, Calif.--(BUSINESS WIRE)--#A2Bio--A2 Biotherapeutics, Inc. (“A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical data related to its proprietary Tmod™ cell therapy platform have been published in Science Translational Medicine and Journal for...